| |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 25/24 | Mar 22/24 | Aurinia Pharmaceuticals | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -199,776 | $4.98 USD |
Mar 25/24 | Mar 22/24 | Aurinia Pharmaceuticals | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 199,776 | $4.98 USD |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Common Shares | 57 - Exercise of rights | 15,688 | |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Common Shares | 57 - Exercise of rights | 9,136 | |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -35,734 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -20,816 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Knappertz, Volker | Direct Ownership | Common Shares | 57 - Exercise of rights | 29,459 | |
Mar 8/24 | Mar 6/24 | Knappertz, Volker | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -63,820 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Greenleaf, Peter | Direct Ownership | Common Shares | 57 - Exercise of rights | 144,781 | |
Mar 8/24 | Mar 6/24 | Greenleaf, Peter | Direct Ownership | Common Shares | 57 - Exercise of rights | 54,787 | |
Sign up or login above to see all SEDI filings within the past 6 months. |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Mar 25/24 | Mar 22/24 | Aurinia Pharmaceuticals | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -199,776 | $4.98 USD |
Mar 25/24 | Mar 22/24 | Aurinia Pharmaceuticals | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 199,776 | $4.98 USD |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Common Shares | 57 - Exercise of rights | 15,688 | |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Common Shares | 57 - Exercise of rights | 9,136 | |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -35,734 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Martin, Michael Robert | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -20,816 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Knappertz, Volker | Direct Ownership | Common Shares | 57 - Exercise of rights | 29,459 | |
Mar 8/24 | Mar 6/24 | Knappertz, Volker | Direct Ownership | Rights Restricted Stock Unit | 57 - Exercise of rights | -63,820 | $5.60 USD |
Mar 8/24 | Mar 6/24 | Greenleaf, Peter | Direct Ownership | Common Shares | 57 - Exercise of rights | 144,781 | |
Mar 8/24 | Mar 6/24 | Greenleaf, Peter | Direct Ownership | Common Shares | 57 - Exercise of rights | 54,787 | |
Sign up or login above to see all SEDI filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. |
Competitors with Recent Insider Filings |
Fennec Pharmaceuticals (T:FRX*CA) |
Satellos Bioscience (T:MSCL*CA) |
XORTX Therapeutics (V:XRX*CA) |